Invasive aspergillosis in 2002: An update

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 21, Issue 3, 2002, Pages 161-172

  Kontoyiannis, D ^a   Bodey, G ^a  

^a Infection Control and Employee Health ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLYLAMINE DERIVATIVE; AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; CORTICOSTEROID; ECHINOCANDIN; FLUCYTOSINE; ITRACONAZOLE; LIPID; LIPOSOME; MICAFUNGIN; NYSTATIN; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; PYRROLE DERIVATIVE; RAVUCONAZOLE; RIFAMPICIN; SCH 59884; TERBINAFINE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; V 002; VER 003; VORICONAZOLE;

ASPERGILLOSIS; ASPERGILLUS; CHRONIC GRANULOMATOUS DISEASE; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG FORMULATION; EARLY DIAGNOSIS; ENVIRONMENTAL FACTOR; EPIDEMIOLOGICAL DATA; EXPOSURE; GRAFT VERSUS HOST REACTION; GRANULOCYTOPENIA; HIGH RISK POPULATION; HOST RESISTANCE; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION CONTROL; MOLECULAR BIOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK; SURGICAL TECHNIQUE; TREATMENT INDICATION;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; CROSS INFECTION; HUMANS; IMMUNOCOMPROMISED HOST; INFECTION CONTROL;

EID: 0036217591     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-002-0699-z     Document Type: Review

References (109)

1. Aspergillus fumigatus and aspergillosis
2. Aspergillosis
3. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital
4. Epidemiology of visceral mycoses: Analysis of data in annual of the pathological autopsy cases in Japan
5. Postmortem analysis of invasive aspergillosis in a tertiary care hospital
6. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients, with special attention to hepatic candidiasis
7. Aspergillus: An increasing problem in tertiary care hospitals?
8. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: Results of population-based laboratory active surveillance
9. Antifungal and surgical treatment of invasive aspergillosis: Review of 2,121 published cases
10. Therapeutic outcome in invasive aspergillosis
11. Aspergillosis case-fatality rate: Systematic review of the literature
12. Invasive aspergillosis (IA) in patients with leukemia and bone marrow transplant (pts): Poor outcome despite aggressive therapy
13. Burden of aspergillosis-related hospitalizations in the United States
14. Fungal infections complicating acute leukemia
15. Pulmonary aspergillosis and invasive disease in AIDS
16. Causes of death in patients with systemic lupus erythematosus in Sao Paulo, Brazil: A study of 113 autopsies
17. Invasive aspergillosis as an opportunistic infection in nonallografted patients with multiple myeloma: A European organization for research and treatment of cancer
18. Invasive pulmonary aspergillosis in a critically ill neonate: Case report and review of invasive aspergillosis during the first 3 months of life
19. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation
20. Invasive pulmonary aspergillosis associated with high-dose inhaled fluticasone
21. Host defense mechanism in Aspergillus fumigatus infections
22. Aspergillus fumigatus conidia induce a TH1-type cytokine response
23. Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus. Observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes
24. Kinetic study of host defense and inflammatory response to Aspergillus fumigatus in steroid-induced immunosuppressed mice
25. Th1 and Th2 cytokines in mice with invasive aspergillosis
26. Pathogenesis I: Interactions of host cells and fungi
27. Cytokines and mycoses
28. Dendritic cell-mediated stimulation of the in vitro lymphocyte response to Aspergillus
29. Human platelets damage Aspergillus fumigatus hyphae and may supplement killing by neutrophils
30. Interferon-gamma and tumor necrosis factor-alpha protect mice from invasive aspergillosis
31. Trends in immunotherapy of fungal infections
32. Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type I responses
33. Cytokine- and T-helper-dependent immunity in murine aspergillosis
34. Elevated serum concentrations of interleukin-10 in non-neutropenic patients with invasive aspergillosis
35. The necrotic gene in Drosophila corresponds to one of a cluster of three serpin transcripts mapping at 43 A1.2
36. Involvement of CD14 and Toll-like receptors in activation of human monocytes by Aspergillus fumigatus hyphae
37. Epidemiology of nosocomial fungal infections: Invasive aspergillosis and the environment
38. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation
39. Hospital epidemiologic surveillance for invasive aspergillosis: Patient demographics and the utility of antigen detection
40. Efficacy of infection control measures during a nosocomial outbreak of disseminated aspergillosis associated with hospital construction
41. Epidemiology and diagnosis of invasive pulmonary aspergillosis in bone marrow transplant patients: Results of a 5-year retrospective study
42. Aspergillus species from hospital air and from patients
43. Clothing spread Aspergillus spores. Current Topics
44. Nosocomial aspergillosis is water-borne
45. Counterpoint: Invasive aspergillosis and the environment - Rethinking our approach to prevention
46. The ins and outs of DNA fingerprinting the infectious fungi
47. Molecular epidemiology of nosocomial invasive aspergillosis
48. Investigation of invasive aspergillosis: Utility of molecular typing with the use of random amplified polymorphic DNA probes
49. Molecular epidemiology of apparent outbreak of invasive aspergillosis in a hematology ward
50. Comparison of restriction fragment length polymorphism, microsatellite length polymorphism, and random amplification of polymorphic DNA analyses for fingerprinting Aspergillus fumigatus isolates
51. Genetic diversity among clinical and environmental isolates ofAspergillus fumigatus
52. Molecular typing of environmental and patient isolates of Aspergillus fumigatus from various hospital settings
53. Molecular epidemiology study of Aspergillus fumigatus in a bone marrow transplantation unit by PCR amplification of ribosomal intergenic spacer sequences
54. Significance of aspergillemia in patients with cancer. A 10-year study
55. Diagnostic yield of bronchoscopy in histologically proven invasive pulmonary aspergillosis
56. Aspergillosis update
57. Culture yield from immunosuppressed cancer patients with invasive aspergillosis
58. Aspergillosis. The spectrum of the disease in 98 patients
59. Management of invasive pulmonary aspergillosis in hematology patients: A review of 87 consecutive cases at a single institution
60. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery
61. Early diagnosis of invasive aspergillosis
62. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive aspergillosis
63. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: A prospective validation
64. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus
65. Evaluation of PCR for detection of DNA specific for Aspergillus species in sera of patients with various forms of pulmonary aspergillosis
66. Early detection of Aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening
67. Use of real-time PCR on blood samples for diagnosis for invasive aspergillosis
68. Comparison between plasma and whole blood specimens for detection of Aspergillus DNA by PCR
69. Prediction of invasive pulmonary aspergillosis from colonisation of lower respiratory tract before marrow transplantation
70. Detection of Aspergillus species in blood and bronchoalveolar lavage samples from immunocompromised patients by means of 2-step polymerase chain reaction: Clinical results
71. Microbiological diagnosis of invasive fungal infections in transplant recipients
72. Quantitative galactomannan detection is superior to PCR in diagnosing and monitoring invasive pulmonary aspergillosis in an experimental rat model
73. Comparison of serum galactomannan antigen detection and competitive polymerase chain reaction for diagnosing invasive aspergillosis
74. New perspectives in the diagnosis of systemic fungal infections
75. Practice guidelines for diseases caused by Aspergillus
76. Invasive aspergillosis: Disease spectrum, treatment practices, and outcomes
77. Treatment strategies for Aspergillu s infections
78. Therapy of Aspergillus fumigatus-related diseases
79. Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients
80. A clinical perspective for the management of invasive fungus infections. Focus on IDSA guidelines
81. Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses
82. Concepts in design of comparative clinical trials of antifungal therapy in neutropenic patients
83. Lipid-based antifungal agents: Current status
84. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis
85. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients
86. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia
87. Progressive disseminated aspergillosis in a bone marrow transplant recipient: Response with high dose of liposomal amphotericin B
88. Safety, tolerance and pharmacokinetics of high-dose liposomal amphotericin B (AmBi-some) in patients infected with Aspergillus species and other filamentous fungi: Maximum tolerated dose study
89. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal ampho-tericin B for treatment of invasive aspergillosis
90. Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria
91. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS
92. Treatment failure in invasive aspergillosis due to poor tissue penetration by antifungal agents
93. Surgical therapy for pulmonary aspergillosis in immunocompromised patients
94. Pulmonary resection for invasive Aspergillus infections in immunocompromised patients
95. Surgical management of invasive pulmonary aspergillosis in neutropenic patients
96. Clinical pharmacology of systemic antifungal agents: A comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development
97. An open, non-comparative multicenter study to evaluate efficacy and safety of posaconazole (SCH 56592) in the treatment of invasive fungal infections (IFI) refractory (R) to or intolerant (I) to standard therapy (ST)
98. The efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
99. Open, randomized comparison of voriconazole (VRC) and amphotericin B (AmB) followed by other licensed anti-fungal therapy (OLAT) for primary therapy of invasive aspergillosis (IA)
100. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosup-pressed mice
101. Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin (CAS) in adults with invasive aspergillosis (IA) refractory (R) or intolerant (I) to amphotericin B (AMB), AMB lipid formulations (lipid AMB), or azoles
102. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy
103. The past, present and future of antimycotic combination therapy
104. Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: An E-test-based strategy
105. Drug interaction in vitro between a polyene (AmBisome; AmBi) and an echinocandin (FK463) vs. Aspergillus species
106. Problems of antifungal in vitro testing in Aspergillus fumigatus
107. In vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis
108. Lack of correlation in in vitro amphotericin B susceptibility testing with outcome in a model of Aspergillus infection
109. Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literature